A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects

OBJECTIVE: SB2, a biosimilar to infliximab reference product (INF), has an identical amino acid sequence and similar physicochemical functional properties to its reference product. The primary objective of this study is to demonstrate pharmacokinetic (PK) bioequivalence between SB2 and EU-sourced IN...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BioDrugs
Hlavní autoři: Shin, Donghoon, Kim, Youngdoe, Kim, Yoo Seok, Körnicke, Thomas, Fuhr, Rainard
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2015
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4684585/
https://ncbi.nlm.nih.gov/pubmed/26577771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0150-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky